InvestorWire NewsRoom

Articles

Articles Category: Biotechnology
Thursday Oct 21, 2021 - 12:26 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announced Inclusion in AdvisorShares Psychedelics ETF; KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

Tryp announced its inclusion in the AdvisorShares Psychedelics ETFThe company hopes that its participation will open it up to a more diverse shareholder base and broaden its life science exposure Tryp’s presentation at the KCSA Virtual Investor Conference will also be available for on-demand viewing over the next 90 days Launched back in September 2021, the AdvisorShares Psychedelics Exchange-Traded Fund (“ETF”) has been actively trading, focusing…

Continue Reading

Wednesday Oct 20, 2021 - 1:40 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine

Substances such as psilocybin, ketamine and LSD are edging into mainstream culture, setting the stage for a paradigm shift in modern medicineCybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalationThe company is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications Earlier this month, a Time magazine article reported on the “new era”…

Continue Reading

Tuesday Oct 12, 2021 - 1:21 pm

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Among Leading Biotech Companies Innovating the Field of Early Cancer Screening and Detection

Blood and genomic testing are becoming preferable means of early cancer screening and detectionLeaders innovating this niche of the medical industry include AnPac Bio, Grail, Thrive and GuardantAnPac Bio-Medical's testing features a database of more than 200,000 commercial and research multi-cancer test samples (probably the largest multi-cancer test data base) that detect up to 26 different types of cancerOne of the few companies offering multi-cancer…

Continue Reading

Friday Oct 08, 2021 - 1:48 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Launch of New Website and Resources

Tryp Therapeutics recently launched a new website with updated resources to be featured on the siteOver the next few weeks, the company will share key resources that will be the standout features of the new websiteTryp believes that the new features represent expanded knowledge of the company’s strategy and will present more opportunities to existing investors and bring in more individuals who share in its…

Continue Reading

Friday Oct 08, 2021 - 11:36 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces New Executives, Internal Promotions

Cybin names Dr. Amir Inamdar as chief medical officer for European operationsThe company appoints Dr. Geoff Varty as head of research and developmentBoth professionals bring decades of expertise to their new roles as Cybin focuses on progressing psychedelic therapeutics As Cybin (NEO: CYBN) (NYSE American: CYBN) continues its commitment to focus on the psychedelic therapeutic space and deliver proprietary drug-discovery platforms, the company has made…

Continue Reading

Tuesday Oct 05, 2021 - 12:58 pm

RYAH Group Inc. (CSE: RYAH) Reveals Attendance at the Wall Street Reporter’s Next Super Stock Livestream Conference

RYAH Group is a digital healthcare analytics and technology company focused on developing tools that provide patients and doctors with the ability to accurately manage the intake in plant-based treatmentThe company recently revealed its participation at the Wall Street Reporter’s ‘Next Super Stock’ livestream conference held on September 23, 2021 RYAH Group (CSE: RYAH) is a leading digital health care analytics and technology company with…

Continue Reading

Thursday Sep 30, 2021 - 10:58 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Achieves Most Important Milestone Yet with Submission of IND Application for Phase 2a Clinical Trial

Tryp Therapeutics on September 22 submitted an IND application to the FDA to evaluate its oral formulation of synthetic psilocybin, TRP-8802, in a Phase 2a clinical studyThe study seeks to evaluate TRP-8802 for the treatment of patients with eating disorders and will enroll 10 patients According to Tryp Chairman and CEO, the submission is the first of several IND filings the company intends to make in…

Continue Reading

Tuesday Sep 28, 2021 - 12:32 pm

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) 10 Years in the Making: Innovation Leads to Multi (Pan)-Cancer Screening

After ten years, the concept of (multi)pan-cancer screening pioneered by AnPac Bio-Medical Science Co., Ltd. (AnPac Bio) has finally been accepted and the industry is shifting toward early screening technology that detects multiple cancers in blood at one time. In 2010, AnPac Bio proposed the theory of multi-cancer screening. At the time, the industry was divided over this innovative approach. The Company, however, persevered with…

Continue Reading

Tuesday Sep 28, 2021 - 11:14 am

RYAH Group Inc. (CSE: RYAH) Provides Insight into Cannabis Medical Space in Brazil

Medical cannabis reform in Brazil is slowly taking shapeChallenges include the cost of medical cannabis products and medical cannabis patients living close to available accessWith its background in connected devices, big data, and technology, RYAH appears well qualified to provide insight on medical cannabis around the world While the cannabis world’s attention is often focused on what’s happening in North America, activity in Latin America…

Continue Reading

Monday Sep 27, 2021 - 1:24 pm

Nemaura Medical Inc. (NASDAQ: NMRD) Reveals Attendance at This Year’s H.C. Wainwright Global Investment Conference

Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devicesThe company recently revealed its participation at the annual H.C. Wainwright Global Investment Conference, held between September 13-15, 2021Through its sugarBEAT flagship product, Nemaura has sought to capitalize on the expanding Type 2 Diabetes market, expected to reach an annual value of $59 billion by 2025 Nemaura Medical (NASDAQ: NMRD) is a…

Continue Reading

Monday Sep 27, 2021 - 11:57 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Mental Health Treatment Innovation

WHO survey reports that mental health services in 93% of countries around the world have been disrupted or halted as a result of COVID-19People with pre-existing mental, neurological or substance-use disorders are more vulnerable to SARS-CoV-2 infectionCybin is on a mission to revolutionize mental healthcare A World Health Organization (“WHO”) survey covering 130 countries is calling attention to the fact that today’s demand for mental…

Continue Reading

Monday Sep 27, 2021 - 10:30 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leading the Way in Early Cancer Detection Space

Up to 50% of cancer is preventable, while other types can be detected or treated early, often resulting in complete remission for patientsAnPac Bio-Medical Science Co., Ltd. uses blood-based testing to detect many types of cancer (multi-cancer tests) and pre-cancer diseases, predicting its potential to occur in the futureCompany’s proprietary CDA technology is powered by a database of over 220,000 clinical and general population test…

Continue Reading

Friday Sep 24, 2021 - 6:01 am

Brain Scientific Inc. (BRSF) is Making EEGs Accessible to 5,900 US Hospitals

5,900 hospitals in the US lack the necessary extensive EEG techBRSF has created a cost-effective solution capable of supplying these hospitals with the equipment needed and broadening the reach of each neurologistEmergency departments and hospitals are not the only markets in need of brain monitoring devices, and the industry is expected to grow to $208 billion by 2023 For most U.S. patients, an EEG is…

Continue Reading

Thursday Sep 23, 2021 - 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates

Pharmaceutical company Tryp Therapeutics is preparing for clinical trials evaluating synthetic formulations of psilocybin to treat medical conditions with underpinning neurological causesThe clinical trials planned are being conducted in partnership with research teams at the University of Florida and the University of MichiganTryp executives have been meeting with investors at select conferences recently to increase awareness, including the just-completed Sept. 21 presentation at Oppenheimer’s Fall…

Continue Reading

Wednesday Sep 22, 2021 - 9:00 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receives College of American Pathologists Accreditation for U.S. Laboratory

AnPac Bio’s clinical laboratories are located in the U.S. and China, with a total of 142 patents issued as of March 2021Cancer Differentiation Analysis (“CDA”) technology is AnPac Bio’s approach to early cancer detection and screening technology, with over 200,000 samples and cases to serve as a way of approaching cancer screeningCompany’s ownership percentage in subsidiary AnPai (Shanghai) Healthcare Management Consultant Co. Ltd. has increased…

Continue Reading

Tuesday Sep 21, 2021 - 2:20 pm

The Cannabis Society, European Medical Cannabis Conference To Showcase World Leaders For Discussions On The Growing World Cannabis Ecosystem

European Medical Cannabis Conference Tue, Sep 21 at 9:00 AM-5:00 PMHybrid Conference - Virtual and In-PersonPhysical Venue: Schützenstraße 73, 10117 Berlin, Germany MSO Growth and Consolidation Cannabis Conference  Tue, Sep 21 at 9:00 AM-5:00 PMVirtual Conference only The European Medical Cannabis Conference and the MSO Growth and Consolidation Conference, organized by The Cannabis Society, invites medical professionals, professors, distributors, and experts for its hybrid physical/online…

Continue Reading

Monday Sep 20, 2021 - 12:48 pm

RYAH Group Inc. (CSE: RYAH) Devices Ideal for Implementation of New Cannabis Intake Control Recommendations

Research team uses Delphi process for the first time to identify ideal cannabis dosing guidelines.After several rounds of voting, the ‘global task force’ created three separate dosing protocols.RYAH Group’s suite of precision dosing devices provide a practical way to safely execute these — or any — recommended dosing guidelines. Dosing recommendations are critical in any health treatments, but where cannabis is concerned, dosing levels have…

Continue Reading

Friday Sep 17, 2021 - 9:15 am

Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’

Nemaura’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed for people with diabetes and prediabetessugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union, and Nemaura has submitted a premarket approval application to the U.S. FDANemaura continues to build a world-class management teamNemaura plans to launch a direct to consumer…

Continue Reading

Friday Sep 17, 2021 - 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Signs Definitive Agreement to Acquire 100% of BayMedica Inc., Positioning it to Stand Distinct in Rare Cannabinoids Manufacturing, Become a Revenue-Generating Company, Expand Drug Development Capabilities

InMed Pharmaceuticals recently announced it has entered a definitive agreement to acquire 100% of BayMedica Inc.BayMedica is a private company that specializes in the manufacture and commercialization of rare cannabinoidsUpon closing, the transaction will make InMed a global leader in the manufacturing of rare cannabinoids in addition to transforming it into a revenue-generating companyAcquisition provides InMed with the complete flexibility across multiple manufacturing approaches On…

Continue Reading

Friday Sep 17, 2021 - 9:00 am

Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

Pharmaceutical company Tryp Therapeutics is pursuing novel solutions to medical conditions with unmet needs, working to establish the efficacy and safety of the company’s trademarked synthetic psychedelic drug candidateThe company’s products — TRP-8802 and TRP-8803 — aim to provide new therapies for select eating disorders with specific neurological causes, as well as pain and addition concernsTryp is preparing Phase 2a and Phase 2b clinical trials…

Continue Reading

Wednesday Sep 15, 2021 - 1:39 pm

Potential for Psychedelic treatments Drives Mind Cure Health Inc.’s (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Strategy for Therapeutics Profitability

Canada-based life sciences company Mind Cure Health is developing a synthetic form of the psychedelic drug ibogaine as part of its efforts to take a leading position in the burgeoning market for mental health therapiesPsychedelics, strengthened by new clinical research driving scientific and legislative openness to the drugs’ possible benefits under controlled conditions, are overcoming stigmas   that arose from recreational use of the drugMind…

Continue Reading

Monday Sep 13, 2021 - 2:06 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Innovation, Partnerships, and Leadership: A 2021 Outlook

So far in 2021, Tryp’s innovations have allowed it to position itself as a first-mover in the psychedelics spaceThe company has announced completion of psychotherapy training for the upcoming phase 2a clinical trials for specific overeating disordersTryp has also been keen on collaborating and partnering with key players in the industry, such as Calvert Labs and Gad Consulting services, the University of Michigan, and the…

Continue Reading

Friday Sep 10, 2021 - 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) CEO Discusses Psychedelics, Company’s Progress, Plans, Business in a Recent Bell2Bell Podcast Interview

Mind Cure Health Inc. CEO Kelsey Ramsden was featured in a recent Bell2Bell podcast interview, during which she explained the company’s primary focal points – digital therapeutics and drug developmentOn the digital therapeutics side of its business, the company is developing iSTRYM, a clinical-grade, evidence-backed, science-based, AI-driven tool for both therapists and patients, scheduled for full commercial launch in Q1 2022MCUR has successfully synthesized the…

Continue Reading

Thursday Sep 09, 2021 - 11:22 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share Updates on Its PFN Program Pipeline at the Upcoming H.C Wainwright 23rd Annual Global Investor Conference

Tryp Therapeutics is set to present at the H.C Wainwright 23rd Annual Global Investor Conference scheduled for Sept. 13-15, 2021Greg McKee, company chairman and CEO, will provide an overview of the business and its pipeline, including the Psilocybin-for-Neuropsychiatric Disorders (“PFN”) programTryp’s presentation will be available on-demand from 7.00 a.m. EDT on Sept. 13Through the PFN program, Tryp is focused on developing psychedelic compounds targeting diseases…

Continue Reading

Wednesday Sep 08, 2021 - 9:30 am

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Symposium Highlights the Application of Biophysical Technology in Cancer Prevention and Treatment

AnPac Bio-Medical Science Co., Ltd. held its 2021 technical symposium, entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment” in Shanghai, China, on August 6, 2021The symposium included attendees from various hospitals, universities, and Fortune 500 companies, including Thermo Fisher Scientific and AnPac Bio’s contract partner Roche Pharmaceuticals ChinaA recent report from Frost & Sullivan ranked AnPac Bio at #3 in the world…

Continue Reading

Wednesday Sep 08, 2021 - 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Training for Upcoming Phase 2a Psychedelics Trial Targeting Eating Disorders

Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needsThe company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select eating disorders in combination with psychotherapyTryp recently announced that its educational…

Continue Reading

Friday Sep 03, 2021 - 11:07 am

Brain Scientific Inc. (BRSF) Addressing Immediate and Long-Term Needs of the Neurological Marketplace

The need for neurological services is increasing while the gap in access to care for patients is only increasingNeurological services are facing the challenge of a more contagious variant, staff shortage, and trying to uncover the reason for long-term symptoms in those who have had COVID Brain Scientific (OTCQB: BRSF), a commercial stage healthcare company, is bridging the widening gap in patient access to care.…

Continue Reading

Wednesday Sep 01, 2021 - 9:59 am

With a Focus On AI and ML Technology, Brain Scientific Inc. (BRSF) Is Positioned to Take The Lead in Growing EEG Market

Brain Scientific focused on leveraging AI and ML to detect neurological diseases, aims to create comprehensive database of brain biomarkers to increase diagnosis accuracyBrain Scientific positioned to disrupt EEG market with FDA-cleared patented products that provide cost-effective brain imaging in any settingCurrent global EEG device market estimated at $956.1 million with CAGR of 8.7% from 2019 to 2026, expected to reach $1.6 billion by 2026…

Continue Reading

Friday Aug 27, 2021 - 1:28 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), At the Forefront of the Psychedelic Renaissance

Psychedelics date back to ancient times, with records showing their use among the Aztecs as well as cultures in North Africa and Europe for medicinal and cultural purposesThe prohibition era marked significant strides in psychedelics research, including the ultimate prohibition of the possession, sale and manufacture of psychedelicsThe 21st century has seen a surge in psychedelics research, a critical factor that has initiated a renaissance…

Continue Reading

Friday Aug 27, 2021 - 10:42 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Presents CBN-Based Treatment for Glaucoma at H.C. Wainwright Ophthalmology Virtual Conference

The presentation highlighted the company’s INM-088 cannabinol topical eye drop to treat glaucomaInMed’s IntegraSyn is being used to help the company develop synthetic bioidentical rare cannabinoids in the lab, as most are only found in trace amounts in cannabis plantsIn addition to INM-088 for glaucoma, the company is currently working on CBN-based INM-755 to treat a rare genetic skin disorder called epidermolysis bullosa and is…

Continue Reading

Thursday Aug 26, 2021 - 10:00 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names CEO of AnPac Bio U.S. to Drive Adoption of Early Cancer Detection Technology

Early cancer detection technology innovator AnPac Bio-Medical Science Co. Ltd. has been awarded 142 patents with 95 patents pending as part of its bid to revolutionize cancer screening protocolsAnPac Bio’s proprietary technology screens for a variety of biophysical properties and analyzes the results to establish risk factors for tumor development before tumor cells begin circulating in the bloodstreamAnPac Bio’s technology can be combined with the…

Continue Reading

Wednesday Aug 25, 2021 - 10:25 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production of Rare Cannabinoids at Pharmaceutical Levels

Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare cannabinoidsInMed Pharmaceutical has developed a trademarked platform called IntegraSyn that extracts five times the normally expected yields of cannabinoids from its plant sourcesIntegraSyn’s ability to increase yields may ultimately help InMed to achieve a profitable means of producing cannabinol (“CBN”) and other lesser-known cannabinoids at commercial scalesTo date, GW Pharma’s…

Continue Reading

Monday Aug 23, 2021 - 10:43 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report

Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchangeCybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEOSeveral of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline Cybin (NEO: CYBN) (NYSE American: CYBN) is wrapping up a highly successful first quarter with…

Continue Reading

Friday Aug 20, 2021 - 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) 2021 Growth Strategy Update

So far in 2021, Mind Cure has embarked on an aggressive plan to strengthen its advisory board and file for new provisional patents for its fully synthetic ibogaine In January, the company also announced an amended agreement to grow the size of an earlier-announced bought deal financing This year has also seen the launch of the second stage of manufacturing of Ibogaine for use in psychedelic clinical research Mind Cure also continues…

Continue Reading

Thursday Aug 19, 2021 - 10:36 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with Calvert Labs, Gad Consulting Services to Conduct Preclinical Bridging Studies in Preparation for Phase 2b Clinical Trials

Tryp Therapeutics recently announced new agreements with Calvert Labs and Gad Consulting Services, the second in a series of upcoming bridging studies aimed at facilitating the advancement of TRP-8803 into Phase 2b clinical trialsCalvert Labs will design and execute the exploratory studies, while Gad Consulting Services will advise on certain aspects of the studies Calvert Labs shall performTRP-8803 and TRP-8802 are psilocybin-based products being evaluated…

Continue Reading

Thursday Aug 19, 2021 - 10:03 am

Brain Scientific Inc. (BRSF) Addresses Growing Epilepsy Problem With Portable Low-Cost Brain Monitoring Devices

CDC reports epilepsy is growing problem, 3.4 million people afflicted in the USAccording to report, adult cases rose from 2.3 million to 3 million between 2010 and 2015, pediatric cases increased 450,000 to 470,000 over same periodBrain Scientific produces patented devices that can be used to provide instant EEG tests to millions of US hospital patients each year More Americans are suffering from epilepsy than…

Continue Reading

Tuesday Aug 17, 2021 - 9:30 am

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary AI Model Predicts Cancer Outcomes, Leads to New Therapies

AI models of genomic data can predict cancer outcomes, which can then help personalize ovarian cancer treatmentsResults come from Helomics’ work on the 100,000 Genomes Project in Genomics England’s National Genomic Research LibraryModel learns patterns in genetic mutations of patients’ tumors, uses that knowledge to predict patient survival In an historic announcement in the space where artificial intelligence and precision medicine intersect, Predictive Oncology (NASDAQ:…

Continue Reading

Tuesday Aug 17, 2021 - 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Welcomes Digital Technology Expert in Development of Doctor-Patient SaaS Tech

Canada-based life sciences company Mind Cure Health is pursuing innovative technology and research solutions to improve mental health through technology The company is focused on developing digital therapeutics technology and researching psychedelic compoundsThe company’s proprietary software-as-a-service (SaaS) platform iSTRYM is designed to increase transparency and awareness between patients and therapists On the research side, Mind Cure Health is also manufacturing synthetic ibogaine and currently determining the commercialization…

Continue Reading

Tuesday Aug 17, 2021 - 9:00 am

Brain Scientific Inc.’s (BRSF) Technology Could Be Part of the Solution as New Research Finds that Neurological Consequences of COVID-19 Could be the Norm Rather than Exception

It has become known that COVID-19 patients can present with neurological symptoms, but new comprehensive cross-country study indicates that it could be more prevalent than previously thoughtThis could represent enormous challenge to healthcare as it needs to prepare for immediate and longer-term rehabilitation care of these patientsBrain Scientific is committed to remaining at forefront of brain diagnostics, potentially offering solution to higher need for neurological…

Continue Reading

Tuesday Aug 17, 2021 - 9:00 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces New Cooperative and Partnership Agreements, and further Strengthens Board of Directors

Cooperation and partnership discussions: AnPac Bio has reported major corporations in the medical industry include Roche Pharmaceuticals China and Advanced Life Therapeutics Co., LtdAnPac Bio holds 40% minority equity in Advanced Life Therapeutics, performing contract R&D on integrated circuit-based components for cancer treatment medical devicesAnPac Bio’s board now includes Mr. Chao Feng who has global fortune 500 Companies’ managerial experience as independent director effective July…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).